Form 4: Athira Pharma CEO Mark Litton Acquires 325,000 Restricted Stock Units and Options
SEC Form 4 Filing
Athira Pharma's CEO, Mark Litton, was granted 325,000 restricted stock units and 325,000 stock options on October 3, 2024, according to a Form 4 filing.
Summary
- Mark James Litton, the President and CEO of Athira Pharma, Inc., filed a Form 4 on October 3, 2024.
- The filing reports the acquisition of 325,000 Restricted Stock Units (RSUs) and 325,000 stock options.
- The RSUs and stock options were acquired on October 3, 2024.
- The exercise price for the stock options is $0.4499.
- Both the RSUs and stock options vest in three equal installments on December 31, 2024, June 30, 2025, and December 31, 2025, contingent upon continued service.
- Each RSU represents a contingent right to receive one share of Athira Pharma's common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of equity to the CEO is a standard practice and aligns his interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedule of the RSUs and stock options suggests an expectation of continued service by the CEO through December 31, 2025.
Industry Context
Granting stock options and restricted stock units to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The specific terms of the grant, such as the vesting schedule and exercise price, are tailored to the company's specific circumstances and goals.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation tools in the biotech industry.
- Companies like Biogen, Amgen, and Gilead Sciences routinely use similar equity-based compensation packages for their executives.
- The vesting schedules (one-third annually) are also typical, aligning with industry norms for incentivizing long-term performance.
Stakeholder Impact
- Shareholders: The grant of equity aligns the CEO's interests with those of shareholders, incentivizing him to increase shareholder value.
- Employees: The grant of equity to the CEO can boost employee morale by demonstrating the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of earliest transaction (acquisition of RSUs and stock options) |
| 10/03/2024 | Date of Form 4 filing |
| 12/31/2024 | First vesting date for one-third of RSUs and stock options |
| 06/30/2025 | Second vesting date for one-third of RSUs and stock options |
| 12/31/2025 | Third vesting date for one-third of RSUs and stock options |
| 10/02/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.